Group One Trading’s ArriVent BioPharma AVBP Stock Holding History

Group One Trading’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Buy	+45,200	New	+$1.02M	﹤0.01%	2674

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Group One Trading's AVBP Position: Q1 2026 in Review

Group One Trading sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 2,854 shares — an estimated $64.5K sold.

Group One Trading first reported a position in AVBP in Q4 2025 and held it in 1 quarter. The position peaked at $57.4K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Group One Trading reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 2,854 ArriVent BioPharma shares in Q1 2026, an estimated $64.5K.
Group One Trading first reported a position in ArriVent BioPharma in Q4 2025 and held it in 1 quarter.
Group One Trading's ArriVent BioPharma position peaked at $57.4K in Q4 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.